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The 2.3-kb BamHI-U DNA fragment (map units 0.319–0.335) of herpes simplex virus type 1 (HSV-1) genome contains the
complete UL25 open reading frame (ORF). It specifies an essential viral protein reported previously to be involved in virus
penetration and capsid assembly (C. Addison, F. J. Rixon, J. W. Palfreyman, M. O’Hara, and V. G. Preston, Virology 138, 246–
259, 1984). To identify the protein encoded by the UL25 gene, the UL25 ORF was cloned in a eukaryotic expression vector
(p91023) downstream of the adenovirus major late promoter to generate the expression plasmid p9-UL25. Synthesis of a
60-kDa protein was observed in COS-7 cells transfected with p9-UL25 plasmid DNA, but not in cells transfected with p91023
control plasmid DNA. To identify and characterize the UL25 protein from HSV-1-infected cells, we prepared a rabbit
antiserum by using UL25-GST fusion protein expressed in Escherichia coli as immunogen. This rabbit antiserum readily
immunoprecipitated the 60-kDa UL25 protein from HSV-1-infected cells. In HSV-1-infected cells, UL25 protein was expressed
as a late (g) or a leaky late (g1) viral protein. The rabbit antiserum raised against HSV-1 UL25 protein immunoprecipitated
a UL25-homologue of identical size from HSV-2-infected cells. However, the reactivity of the antiserum with HSV-2 UL25-
homologue was weaker than compared to the corresponding HSV-1 protein. Consistent with its classification as a virion
component, the UL25 protein was found to be associated with purified HSV-1 virions. q 1996 Academic Press, Inc.
Infection of humans by herpes simplex virus type-1 tors but is incapable of penetration unless the cells are
(HSV-1), a neurotropic alpha-herpesvirus, is initiated by treated briefly with a fusogen such as polyethylene glycol
entry of the virus at mucocutaneous surface. The virus (PEG) or are shifted to the permissive temperature (12).
entry process is thought to be mediated by the interaction Interestingly, certain ts mutants (e.g., tsB5) and null mu-
of viral glycoproteins (gC and gB) with the abundant cell tants in gB are similarly impaired, being able to bind to
surface heparan sulfate proteoglycans which serve as cells but penetrating them only after a brief PEG treat-
the receptors for the virus (1, 2). Following initial attach- ment (4, 13, 14).
ment to the cell surface entry of HSV into the cells is The UL25 protein is apparently multifunctional since a
achieved by fusion of the viral envelope with the cell defect in capsid assembly is also observed if ts1204
surface. is allowed to penetrate cells at permissive temperature
The mechanism of virus–cell fusion (virus penetration) before being shifted to nonpermissive temperature. The
and cell–cell fusion (virus spread) with HSV has not been capsids formed by ts1204 did not contain DNA (12), remi-
fully characterized. However, at least four viral glycopro- niscent of B-type capsid structures. It is well-known that
teins gB, gC, gD, and gH (3–11) are known to mediate herpesvirus-infected cells contain three type of capsid
virus entry. Glycoprotein C facilitates the initial binding structures designated A (empty), B (intermediate), and C
event, whereas gB, gD, and gH are thought to function (full), that can be separated by velocity sedimentation
at a step subsequent to this event. Interestingly, an HSV- through sucrose gradients (15–19). Taken together the
1 protein encoded by the essential UL25 gene which studies of ts mutants in the UL25 gene suggest that it is
lacks sequence motif(s) characteristic of membrane pro- a virion component which functions in virus entry and
teins has been reported to play a role in virus penetration. capsid assembly.
Evidence for this derives from studies with ts1204, a The UL25 gene is located in the BamHI-U fragment
mutant with a defect in the UL25 gene, which at nonper- contained in the unique long (UL) component of the HSV-
missive temperature binds strongly to cell surface recep- 1 genome (Fig. 1). DNA sequence analysis has revealed
that the UL25 ORF in HSV-1 strain 17syn/ is composed
of 580 amino acids, with a predicted molecular weight1 To whom correspondence should be addressed. Fax: (818) 301-
8986. of 62.6 kDa (20). The UL25 gene is conserved among
2780042-6822/96 $12.00
Copyright q 1996 by Academic Press, Inc.
All rights of reproduction in any form reserved.
/ 6A0f$$7709 01-04-96 19:40:14 vira AP-Virology
279SHORT COMMUNICATION
encoding COOH terminal domain of UL25 protein at the
SmaI–EcoRI site of pGEX-3X. This ligation results in an
inframe fusion between GST and 239 amino acid COOH-
terminus of HSV–1UL25 protein. A schematic represen-
tation of the construction of pGST–UL25 plasmid is given
in Fig. 1, together with the map location of UL25 gene in
the HSV-1 genome. The DNA sequence of the junction
region of GST with UL25 in plasmid pGST–UL25 was
determined to confirm inframe ligation (not shown). Upon
induction with isopropyl b-D-thiogalacto-pyranoside
(IPTG) the plasmid pGST–UL25 directed the synthesis
of an approximately 50-kDa UL25–GST fusion protein in
E. coli which is in agreement with the size predicted for
the UL25–GST fusion protein (not shown). The glutathi-
one–Sepharose affinity purified UL25–GST fusion pro-
tein was used to immunize rabbits for the production of
polyclonal antiserum to HSV-1 UL25 protein. Briefly, a
rabbit (R8-3) was immunized with 200–500 mg of purified
UL25–GST fusion protein in 0.5 ml of sterile saline mixed
with 0.5 ml of Freund’s complete adjuvant (DIFCO). Inocu-FIG. 1. (Top) Genome location and restriction enzyme (BamHI, HpaI,
lations were 10 subcutaneous injections (0.1 ml per site)and KpnI) map of HSV-1 BamHI-U DNA fragment (map units 0.319–
0.335); the ATG and TGA codons for UL25 ORF are indicated. (Bottom) on the shaven back. Immunizations were carried out on
Schematic representation of the construction of the eukaryotic expres- Days 1, 14, 28; blood collection (from ear vessel) was on
sion plasmid p9-UL25 and the bacterial expression plasmid pGST- Day 21, and thereafter, every other week. Preimmuniza-
UL25. Prior to ligation in both construct (p9UL25 and pGST-UL25) the
tion serum and antisera were stored at 0207. For radio-3* and/5* ends were modified to acquire the appropriate restriction
immunoprecipitation using HSV-infected CV-1 cells thesites. The restriction sites in parentheses represent those derived from
pUC19 polylinker region. antisera and preimmune sera were pretreated with ace-
tone powder prepared from CV-1 cells to remove nonspe-
cific reactivity.
other alpha-herpesviruses including varicella zoster virus To characterize the polypeptide encoded by the UL25
(VZV; gene 34) and equine herpesvirus-1 (EHV-1; gene ORF we constructed an expression plasmid p9-UL25 as
36) (21, 22). Holland et al. (23) have identified five tran- described in Fig. 1. It contains the 2.3-kb BamHI-U DNA
scripts (5.6, 5.2, 4.4, 2.4, and 1.6 kb) originating from the fragment (map units 0.319–0.335) representing the com-
HSV-1 BamHI-U DNA fragment. Of these at least two (5.6 plete UL25 ORF oriented to facilitate expression under
and 5.2 kb) could potentially encode the UL25 protein. the control of adenovirus major late promoter. The 2.3-
However, nothing is known about the protein product kb BamHI-U DNA was subcloned from plasmid pSG-18
specified by the UL25 ORF (1). To characterize the UL25 (23, 25) into the eukaryotic expression vector p91023 (26,
protein, and to study its role in HSV life cycle, we pre- 27). COS-7 cells transfected with p9-UL25 or a control
pared a rabbit polyclonal antiserum to UL25, using a plasmid p91023 lacking an insert were labeled with
UL25–GST fusion protein expressed in Escherichia coli Tran[35S]-label and the UL25 protein was immunoprecipi-
as immunogen. tated using a rabbit polyclonal antiserum to HSV-1 UL25
In this communication, we report the identification and protein. The UL25 antiserum specifically immunoprecipi-
characterization of the UL25 protein of HSV-1. To the tated a 60-kDa protein from p9-UL25-transfected COS
best of our knowledge, the present study represents the cells (Fig. 2A, lane b). This protein band was absent from
first report on the expression, identification, and charac- cell extracts of COS cells transfected with p91023 and
terization of this essential HSV protein. immunoprecipitated with UL25 antiserum (Fig. 2A, lane
To identify and characterize the UL25 protein, we d) or from cell extracts of COS cells transfected with
needed specific antibodies. Smith and Johnson (24) have p9-UL25 or p91023 and immunoprecipitated with normal
developed plasmid vectors that direct the expression of rabbit serum (Fig. 2A, lanes a and c). The UL25 protein
foreign proteins in E. coli as chimeric proteins by fusion expressed in COS-7 cells comigrated on SDS–PAGE
at the COOH-terminus of sj26, the 26-kDa glutathione with UL25 protein synthesized in HSV-1-infected CV-1
S-transferase (GST; EC 2.5.1.18) derived from parasite cells (Fig. 2A, lane e), indicating that the two proteins
helminth Schistosoma japonicum. A UL25–GST fusion (UL25 expressed in COS-7 cells and UL25 from HSV-1-
protein was expressed using the pGEX-3X vector system infected cells) could not be differentiated on the basis of
(Pharmacia, Piscataway, NJ). Plasmid pGST–UL25 was size or electrophoretic mobility. The apparent 60-kDa
size of the protein is in good agreement with the pre-constructed by ligating a 1.1-kb HpaI–BamHI fragment
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antiserum specifically immunoprecipitated a 60-kDa pro-
tein from HSV-1 (strains F, KOS, and MP)-infected cells
as shown in Fig. 2B. An analogous 60-kDa protein was
also immunoprecipitated from HSV-2 (strains G, 333, and
MS)-infected cells, but the intensity of the band was
much weaker (Fig. 2B). These results show that the 580
amino acid open reading frame in the unique long (UL)
component of HSV-1 genome designated UL25 is ex-
pressed as a 60-kDa protein in CV-1 cells infected with
three different HSV-1 and HSV-2 strains, respectively.
The apparent reduced expression of the HSV-2 UL25
homologue in infected cells was not the consequence
of reduced HSV-2 replication because comparable
amounts of the 140-kDa ribonucleotide reductase large
subunit (RR1 protein) were immunoprecipitated from the
same extracts of HSV-1- and HSV-2-infected cells with
the 51S mAb (not shown; 28). Thus, the UL25 homologue
expressed by the HSV-2 strains reacted weakly with HSV-
1-specific antibody (Fig. 2B), indicating that the HSV-1
and HSV-2 UL25 proteins have diverged, at least in the
239-aa COOH-terminal domain that was used to elicit
the polyclonal antiserum. It is interesting to note that the
UL25 mutant, ts1204, when bound to the cells at the
nonpermissive temperature blocks superinfection by
HSV-1 but not by HSV-2 (12). This has been suggested
to be the consequence of the use of different cell surface
receptors by HSV-1 and HSV-2. An alternative explana-
tion is that the mutant UL25 protein transdominantly inter-
feres with the function of wild-type HSV-1 UL25 protein.FIG. 2. (A) Expression of HSV-1 UL25 protein in COS-7 cells. COS-
We speculate that HSV-2 penetration would be unaf-7 cells were transfected with p9-UL25 (lanes a and b) or p91023 (lanes c
and d) and 35S-labeled proteins were immunoprecipitated using normal fected because sequence divergence of the HSV-2 UL25
rabbit serum (lanes a and c) or rabbit antiserum to HSV-1 UL25 protein protein would preclude it from being susceptible to the
(lanes b and d), respectively. Lane e represents UL25 protein immuno- transdominant effects of the mutant HSV-1 UL25 protein.
precipitated (using UL25 antiserum) from HSV-1 (strain KOS)-infected
To establish the temporal class of the UL25 protein,CV-1 cells included for the sake of comparison. An autoradiogram of
the kinetics of its synthesis were examined by pulseSDS –PAGE gel is shown. The kilodalton values to the left represent
protein size markers. (B) Identification of UL25 protein from HSV-1- and chase labeling experiments. CV-1 cells were mock-in-
HSV-2-infected cells. CV-1 cells were infected with HSV-1 (strains F, fected or infected with HSV-1 and at various times after
KOS or MP) or HSV-2 (strains G, 333, or MS) at a m.o.i. of 5 PFU per infection cells were pulse-labeled for 1 hr with 100 mCi/
cell. At 5 hr after infection cells were labeled with 100 mCi/ml of
ml of Tran[35S]-label. Cells were harvested following aTran[35S]-label for 2 hr. HSV UL25 protein was immunoprecipitated
30-min chase with a 50-fold excess of unlabeled L-methi-using rabbit R8-3 UL25-antiserum. An autoradiogram of electrophoreti-
cally separated proteins is shown. The HSV strain used is noted against onine and L-cysteine, during which time any incompletely
each lane. Lane mock represents mock-infected cells. Position of UL25 synthesized or precursor forms of the protein were con-
protein is indicated by an arrow mark. The kilodalton values to the left verted into the mature form. The UL25 proteins were
represent protein size markers.
immunoprecipitated from cell extracts using rabbit UL25
antiserum. As controls the immediate-early (IE or a) ICP4
and ICP6 and early (E or b) gB proteins were immunopre-dicted size (62.6-kDa) for the UL25 polypeptide con-
sisting of 580 amino acid (20). cipitated from the same cell extracts using 58S, 51S, and
3S mAbs (29–31), respectively, to examine the kineticsOur next objective was to identify the UL25 protein
from HSV-infected cells. For these experiments, CV-1 of synthesis of these proteins in parallel with UL25. The
immunoprecipitated proteins separated on 10% SDS–cells were infected with HSV-1 (strain F, KOS, or MP) or
HSV-2 (G, 333, or MS) and at 5 hr after infection the cells PAGE were visualized by fluorography. The results are
shown in Fig. 3. Synthesis of 60-kDa UL25 protein beginswere labeled with 100 mCi/ml of Tran[35S]-label for 2 hr.
The HSV-1 UL25 or its homologue in HSV-2-infected cells as early as 2 hr after infection (Fig. 3). Maximal (peak
level) synthesis of UL25 was found to occur at 6–9 hrwas immunoprecipitated using the rabbit antiserum to
UL25 and the proteins were analyzed by denaturing poly- postinfection, declining to minimal levels at 16 hr postin-
fection. Maximal (peak level) synthesis of HSV-1 ICP4acrylamide gel electrophoresis (SDS–PAGE). The UL25
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biosynthesis pattern is identical to that of ICP4 is consis-
tent with the presence of the sequence motif TAATGA-
RAT characteristic of IE genes reported by Wymer et al.
(32) for the HSV-2 RR1 gene and Desai et al. (33) for the
HSV-1 RR1 gene, respectively. The two forms of ICP4
observed at IE (0–4 hr) and early (4–9 hr) times after
infection are probably related to the posttranslational
modification of this protein (34). We should note that a
control for a late (g) protein of HSV-1 such as gC was
not included in this experiment.
To distinguish between the possibility that the UL25
protein is an early (b) or a late (g) HSV-1 protein, we
next determined whether the viral DNA replication was
required or not for UL25 synthesis. For these experi-
ments, CV-1 cells were infected with HSV-1 and main-
tained in the presence or absence of 300 mg of phospho-
noacetic acid (PAA; Aldrich) per milliliter added at the
onset of infection (35). Infected cells were labeled with
100 mCi/ml of Tran[35S]-label between 3 and 8 hr after
infection. The radiolabeled UL25 protein, ICP4 (as an
example of IE or a protein), gB (as an example of E or
b protein), and gC (as an example of L or g protein) were
immunoprecipitated from the same cell extracts using
FIG. 3. Kinetics of UL25 protein synthesis in HSV-1-infected cells. antibodies specific to each of these proteins. UL25 pro-
CV-1 cells were mock-infected or infected with HSV-1 (strain F) at a
tein was immunoprecipitated by using rabbit UL25 anti-m.o.i. of 5 PFU per cell. At various times after infection cells were
serum. ICP4 and glycoproteins gB and gC were immuno-labeled with 100 mCi/ml of Tran[35S]-label for 1 hr in a L-methionine-
and L-cysteine-deficient medium and chased with a medium containing precipitated using 58S, 3S, and 5S mAbs, respectively
50-fold excess of L-methionine and L-cysteine for 30 min. UL25 protein (29). Immunoprecipitated proteins were separated by
was immunoprecipitated from cell extracts using a rabbit UL25 antise- SDS–PAGE and located by fluorography. The results are
rum (R8-3). Glycoprotein gB, ICP6, and ICP4 proteins were immunopre-
shown in Fig. 4. Expression of glycoprotein gC, a late orcipitated using mAbs 3S, 51S, and 58S, respectively. Immunoprecipi-
g gene product was diminished to 30% of the controltated proteins were analyzed on 10% SDS–PAGE followed by fluorogra-
phy. Autoradiogram of electrophoretically separated proteins level in the presence of PAA (Fig. 4; lanes gC, 0 and /
immunoprecipitated from HSV-1-infected CV-1 cells is shown. The time PAA). In contrast, the expression of immediate-early (a
points at which radiolabeling was initiated is noted against each lane. protein) ICP4 went up by about 15% in the presence of
0-hr time point actually represents proteins immunoprecipitated from
PAA (Fig. 4; lane ICP4, 0 or / PAA). Accumulation ofinfected cells (extracts) labeled with Tran[35S]-label for 1 hr and then
glycoprotein gB, an early or b gene product appears tochased for 30 min with unlabeled L-methionine and L-cysteine following
a 1-hr adsorption step. 2-hr time point includes a 1-hr adsorption step, remain unchanged in the presence of PAA. There was
2-hr infection step, and subsequent labeling and chase as in 0 hr. The a decrease in the accumulation of UL25 protein in the
specific HSV-1 protein analyzed is noted on the right hand side of each presence of PAA in a manner similar to that observed
panel.
with HSV-1 gC (Fig. 4; lanes gC and UL25, 0 or / PAA).
However, the extent of reduction in the accumulation of
UL25 was significantly less than compared to HSV-1gC,and ICP6 (RR1) were found to occur at 2 hr postinfection,
then declining to undetectable levels at 12 hr postinfec- a true late (g2) viral protein (Fig. 4). Based on these
results it is appropriate to classify UL25 as a late (g) ortion. Although not visible in this exposure, peak-level
synthesis of gB was found to occur at 6 hr postinfection leaky late (g1) HSV-1 protein.
McGeoch and colleagues (20, 36) have classified theand then declining to minimal levels at 16 hr postinfection
in a manner similar to that observed for the UL25 protein. product of HSV-1 UL25 gene as a virion protein. To dem-
onstrate that the UL25 protein is a virion component,Since glycoprotein B is known to be an early (b) protein
of HSV-1, it was considered likely that the UL25 protein extra-cellular HSV-1 virions labeled with Tran[35S]-label
were purified by velocity sedimentation in sucrose gradi-belonged to the early (b) class of HSV-1 proteins. No
protein product characteristic of UL25 was observed in ent essentially according to published methods (37–39).
Briefly, CV-1 cells (grown on two T175 flasks) were in-mock-infected CV-1 cells as compared to HSV-1-infected
cells analyzed under identical conditions (not shown). fected with HSV-1 (F) at a m.o.i. (multiplicity of infection)
of 5 PFU (plaque forming units) per cell. Infected cellsThe other proteins ICP4 and ICP6 analyzed under identi-
cal conditions showed a pattern of biosynthesis charac- were labeled from 6 to 36 h after infection with 50 mCi/
ml of Tran[35S]-label. Extracellular virus concentrated byteristic of IE (a) proteins. The finding that ICP6 (RR1)
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(20, 36). Sedimentation analysis in sucrose gradients has
been used in previous studies to show that HSV-1 ICP4
(37) and ICP0 (38) and HSV-2 ribonucleotide reductase
(39) proteins are associated with purified infectious viri-
ons. Sequence analysis of the UL25 ORF (1, 20) failed to
identify motifs that typify membrane proteins and thus
the UL25 protein may be a component of the tegument.
It is now known that sucrose gradients do not adequately
separate virions from L-particles (tegument-envelope
structures) and therefore a remote possibility does exist
that the UL25 protein is a component of L-particles and
not the virions. The existence of UL25 ts mutants makes
for a strong case that the UL25 protein is a component
of the virions.
In conclusion, we have expressed a GST–UL25 fusionFIG. 4. Expression of UL25 protein in the presence of phosphonoace-
tic acid (PAA), a DNA synthesis inhibitor. CV-1 cells were infected with protein and raised antibodies in rabbits to the fusion
HSV-1 at a m.o.i. of 10 PFU per cell in the presence of 300 mg/ml or protein; using UL25 antibody, it was shown that UL25 is
no PAA added after 1 hr adsorption step. Cells were labeled with expressed in the absence of prior viral DNA synthesis.
Tran[35S]-label between 3 and 8 hr postinfection. UL25 protein was
However, its accumulation was inhibited in the presenceimmunoprecipitated from cell extracts using a rabbit UL25 antiserum.
of the inhibitor, consistent with it being an leaky late (g1)ICP4, and glycoproteins gB and gC were immunoprecipitated using
monoclonal antibodies (mAbs) 58S, 3S, and 5S, respectively. Immuno- viral protein. Additionally, the UL25 protein was shown
precipitated proteins were analyzed on 10% SDS–PAGE followed by to be a component of the virion, in all probability the
fluorography. Depicted in the figure is an autoradiogram of electropho- tegument. The UL25 antibody also reacted with HSV-2
retically separated proteins immunoprecipitated from HSV-1-infected
UL25 homologue, albeit less strongly, reflecting se-CV-1 cells. The data on radioimmunoprecipitation of UL25 using rabbit
quence divergence from the corresponding HSV-1 pro-antiserum, and that on ICP4, gB, or gC radioimmunoprecipitated using
mAbs was derived from separate autoradiograms. Percentage inhibi-
tion (see text) was calculated based on cpm immunoprecipitated using
the corresponding mAbs in the presence or absence of PAA. Numbers
represent protein size markers in kDa.
centrifugation was layered on a 10-ml 20 to 60% (w/v)
continuous sucrose gradient. Centrifugation was at
20,000 rpm for 20 hr at 47 in a SW41 rotor. Ten fractions
(about 1 ml each) were collected from the bottom of the
gradient, and the UL25 protein was immunoprecipitated
from (0.5-ml aliquot) each fraction using rabbit polyclonal
UL25 antiserum. Another aliquot (0.5 ml) of each fraction
was immunoprecipitated using normal rabbit antiserum.
The HSV-1 virus titers (PFU/ml) were determined for each
fraction (using desired dilution from a 10-ml aliquot) by
plaque assay on monolayers of CV-1 cells. Shown in
Fig. 5 are the results from this sedimentation analysis,
together with HSV-1 titers (PFU per ml) determined for
each of the fractions. It is clear that the 60-kDa UL25
protein (peak fraction 4; Fig. 5, autoradiogram) and the
peak of infectious virus particles (fraction 4, see table
FIG. 5. Cosedimentation of HSV-1 UL25 protein with infectious HSV-in Fig. 5) cosediment on a 20–60% sucrose gradient,
1 particles. Extracellular HSV-1 labeled with Tran[35S]-label was appliedindicating that the UL25 protein is associated with HSV-
on a continuous 20 to 60% sucrose gradient. Centrifugation was for 20
1 virions. Similar results (cosedimentation of UL25 pro- hr at 20,000 rpm in a SW41 rotor (47). Fractions (about 1 ml) were
tein and virus infectivity) were obtained when radiola- collected from the bottom of the tube and the UL25 was immunoprecipi-
tated from a 0.5-ml aliquot of each fraction using rabbit UL25 antiserum.beled extracellular virions were purified by centrifugation
Control immunoprecipitations were done in parallel using normal rabbitthrough 5 to 15% Ficoll gradient essentially as described
serum. An autoradiogram of electrophoretically separated proteins isby Szilagyi and Cunningham (40; not shown). The finding
shown together with the HSV-1 titers (PFU per ml) determined for each
that UL25 protein is associated with HSV-1 virions is fraction. The fraction number is noted against each lane. B and T refer
consistent with the suggestion of Addison and col- to the bottom and top of the gradient tube, respectively. The position
of UL25 protein is indicated by an arrow mark.leagues (12) and the classification of McGeoch et al.
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